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REVIEW
CHEYNE-STOKES RESPIRATION IN PATIENTS WITH
CONGESTIVE HEART FAILURE: CAUSES AND
CONSEQUENCES
Geraldo Lorenzi-Filho, Pedro R Genta, Adelaide C. Figueiredo, and Daniel Inoue
Lorenzi-Filho G, Genta PR, Figueiredo AC, Inoue D. Cheyne-Stokes respiration in patients with congestive heart failure:
causes and consequences. Clinics. 2005;60(4): 333-44.
Cheyne-Stokes respiration is a form of periodic breathing in which central apneas and hypopneas alternate with periods of
hyperventilation, producing a waxing and waning pattern of tidal volume. This review focuses on the causes and consequences
of Cheyne-Stokes respiration in patients with congestive heart failure, in whom the prevalence is strikingly high and ranges
from 30% to 50%. Several factors have been implicated in the genesis of Cheyne-Stokes respiration, including low cardiac
output and recurrent hypoxia. The key pathophysiological mechanism triggering Cheyne-Stokes respiration is
hyperventilation and low arterial CO2 (PaCO2) that when below the apneic threshold triggers a central apnea. Hyperventilation
is associated with pulmonary congestion, and Cheyne-Stokes respiration is more prone to occur during sleep, when the
respiratory system is mainly dependent on chemical control. It is associated with recurrent dips in oxygen saturation and
arousals from sleep, with oscillations in blood pressure and heart rate, sympathetic activation and increased risk of ventricular
tachycardia. Cheyne-Stokes respiration is an independent marker of poor prognosis and may participate in a vicious cycle,
further stressing the failing heart.
KEYWORDS: Cheyne-Stokes respiration. Congestive heart failure. Sleep. Control of breathing. Central apnea.
Clinicians generally pay little attention to a patient’s
pattern of breathing.1 This is partly the result of the limita-
tions of physical examination, which is notoriously unreli-
able in assessing changes in tidal volume.2 Therefore, de-
tection of abnormal patterns requires either an unusually
practiced eye or, preferably, an objective method of record-
ing the breathing pattern. Moreover, subtle alterations in
the breathing pattern may manifest themselves only dur-
ing exercise3 or sleep.4 Cheyne-Stokes respiration (CSR) is
the best-known disturbance of the breathing pattern.1 The
periodic irregularity of respiration, characterized by a pe-
riod of apnea followed by breathing that begins almost im-
perceptibly, waxes until it becomes dyspneic then wanes
until apnea follows the last shallow breath, was first de-
scribed by Cheyne, in 1818.5 This particular pattern of
breathing was later recognized as a complication associated
with heart failure by Stokes, in 1854.6 The patient in the
original description suffered from both congestive heart fail-
ure (CHF) and neurologic disease.5 Therefore, the term
Cheyne-Stokes respiration has been used to describe this
abnormal pattern of breathing but not to denote any spe-
cific underlying etiology. It is also not clear from the origi-
nal descriptions whether the apneas were central or obstruc-
tive in nature (ie, absence or presence of respiratory effort
during apnea, respectively). Patients with CHF may present
both central and obstructive sleep apnea,7-15 may convert
obstructive to central sleep apnea during a single night,16
and may present obstructive apneas with a prolonged
ventilatory pattern that mimics Cheyne-Stokes respiration.17
In this text for the sake of simplicity, unless otherwise stated,
Cheyne-Stokes respiration will imply that it is associated
with central apnea (Fig. 1).
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Figure 1 - Polysomnographic recordings of a congestive heart failure presenting Cheyne-Stokes respiration during sleep. The top channels are
related to sleep recordings. The bottom channels trac respiration by monitoring motion of the thorax, abdomen and respiratory flow (nasal
canula). Observe the typical crescendo-decrescendo tidal volume interposed with central apneas
Cheyne-Stokes respiration has for too long been con-
sidered as a physiologic curiosity and not a clinical prob-
lem worthy of diagnosis and specific therapy,4,7 and only
in the last few years has it attracted more clinical atten-
tion, since it has been recognized to be very common
among patients with severe but stable CHF, and it can
cause symptoms of a sleep apnea syndrome.4,7-13 In pa-
tients with severe but stable CHF, Cheyne-Stokes respi-
ration is present in 30% to 50% of the patients.13,14 It is
present in CHF of all origins, including Chagas dis-
ease.14,15 There is increasing evidence to suggest that
Cheyne-Stokes respiration in patients with CHF partici-
pates a vicious cycle that further stresses the failing
heart. In line with this hypothesis, we have shown that
periodic oscillations of ventilation in normal subjects
promoted profound oscillations in blood pressure and
heart rate;18 similar cardiovascular effects were present
in CHF patients during Cheyne-Stokes respiration19; and
periodic ventricular premature beats were found to be
higher during periods of this respiration than during pe-
riods of regular breathing in CHF patients.20 We have
also recently reported that a mild form of Cheyne-Stokes
respiration, characterized by periodic and cyclic oscil-
lations of minute ventilation (also known as periodic
breathing) was present in 30% of a population of CHF
patients evaluated for heart transplant and was a power-
ful predictor of mortality.3 These findings may help to
explain the increased mortality observed in CHF patients
presenting Cheyne-Stokes respiration observed in some
studies.21-23 This review will focus on the causes and con-
sequences of Cheyne-Stokes respiration in patients with
CHF. We will also briefly review concepts concerning the
control of breathing. More extensive reviews on this
topic have been recently published.4,24-27
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CONTROL OF BREATHING
The respiratory and the cardiovascular systems act in
concert to transfer oxygen (O2) and carbon dioxide (CO2)
between the atmosphere and the cells. Their control sys-
tems must be integrated to ensure that the metabolic needs
of the tissues are met under varying conditions according
to demands.28 Under normal conditions, ventilation is sta-
ble and maintains arterial blood gas tensions within nar-
row limits through a negative feedback circuit. This nega-
tive feedback system consists of a central controller sensi-
tive to fluctuations in PaO2 and PaCO2 at the peripheral and
central chemoreceptors and a mechanism (the lungs, chest
wall, and respiratory muscles) that generates ventilation.29,30
The controlled variables are PaO2, PaCO2, and pH, which
act as negative feedback signals to the central controller.
In turn, the central controller maintains blood gas
homeostasis by altering its neural output to the respiratory
muscles in order to move the chest wall to achieve the ap-
propriate level of ventilation. PaO2 and PaCO2 are altered
accordingly. The system is stable, and the responses are lin-
ear over a wide range of PaCO2. However, apnea may pre-
vail when the PaCO2 is driven below the apneic threshold.29
On the other hand, blood gas homeostasis is maintained
through certain stabilizing influences inherent in the sys-
tem. These include the maintenance of PaCO2 well above
the threshold for apnea, a relatively low gain of the
chemoreceptors, a short delay in the transmission of the ef-
fects of ventilation on PaO2 and PaCO2 to the
chemoreceptors, the rapid correction of deviations in blood
gas tensions toward the desired level, and a high functional
residual capacity acting as a large reservoir of O2 and CO2
within the body to damp oscillations in PaO2 and PaCO2
during apneas.24,25,29,30
During sleep, the respiratory system is particularly prone
to instability. As one passes from wakefulness to nonrapid
eye movement (NREM) sleep, the waking neural drive to
breathe is abolished, and the behavioral control system be-
comes quiescent. Therefore, the nonchemical drive to
breathe associated with wakefulness, which tends to main-
tain ventilation even when PaCO2 is driven below the apnea
threshold, is lost during sleep and breathing becomes criti-
cally dependent on the metabolic control system.29-32 In ad-
dition, during NREM sleep the threshold for a ventilatory
response to CO2 is increased, so that a higher PaCO2 is nec-
essary to stimulate breathing as compared to the awake
state.28,29 If the PaCO2 during wakefulness is below this new
threshold level during sleep, there will be a loss of respira-
tory drive resulting in a central apnea in the transition
awake-sleep. During apnea, PaCO2 rises (at a rate propor-
tional to metabolic CO2 production) until it reaches the
critical threshold value, and breathing resumes. If sleep be-
comes firmly established at this point, regular breathing fol-
lows.29 However, should the central nervous system state
shift back momentarily to the awake state, as occurs dur-
ing arousals from sleep, the increased PaCO2 level that was
present during sleep now represents a state of relative hy-
percapnia for wakefulness. Accordingly, a period of
hyperpnea follows, in accordance with the awake
ventilatory response to CO2, resulting in the hyperpneic
phase of periodic breathing. As long as the central nervous
system state continues to fluctuate between wakefulness
and sleep, waxing and waning of the waking neural drive
results in alternating periods of hyperpnea and apnea until
sleep becomes firmly established. Hence, transitions in
sleep-wakefulness states are an ideal setting for the genera-
tion of respiratory instability and periodic breathing even
in normal humans.33 Similarly, sleep-awake transitions may
produce respiratory control instability by a different mecha-
nism: upper airway instability. Sleep is associated with loss
of muscle tone, rendering the upper airway prone to col-
lapse. In patients with partial or complete airway collapse
at sleep, a central neural output to the respiratory muscles
will not be rapidly translated into airflow. As a consequence,
ventilation may be not sufficient during periods of upper
airway collapse and, a moment later, will overshoot during
brief arousals (when upper airway patency is reestablished).
This mechanism may also lead to fluctuations of PaCO2
above and below the apneic threshold.30
CAUSES OF CHEYNE-STOKES RESPIRATION
The key pathophysiologic mechanism leading to
Cheyne-Stokes respiration is a fluctuation of PaCO2 above
and below the apneic threshold.4,7,24,25 In patients with CHF,
a number of destabilizing factors contribute to fluctuation
in PaCO2. First, a low PaCO2 close to apneic predisposes to
the development of central apneas. Under this condition, a
relatively small increase in ventilation would drive PaCO2
below threshold and trigger a central apnea.4,7,24,25,34
Naughton et al.35 and Hanly et al.36 have shown that CHF
patients with Cheyne-Stokes respiration have lower PaCO2
both while awake and asleep than those without Cheyne-
Stokes. In patients with CHF, an association between
Cheyne-Stokes and low PaCO2 both during wakefulness and
NREM sleep has been demonstrated in several reports.35-40
Naughton et al.35 found that CHF patients with Cheyne-
Stokes respiration had lower PaCO2 during wakefulness and
NREM sleep than patients without it, who had comparable
age, LVEF, PaO2, and lung-to-chemoreceptor circulatory de-
lay. All episodes of Cheyne-Stokes respiration starting dur-
ing stage 2 sleep were almost always, precipitated by hy-
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perventilation in association with arousals from sleep. Fur-
thermore, during Cheyne-Stokes episodes in stage 2 sleep,
PaCO2 fell on average by 1.5 mm Hg, which mirrored a 23%
rise in minute ventilation.35
Patients with CHF and Cheyne-Stokes respiration have
an unusual response to the sleeping state, in that their PaCO2
levels do not increase as they go from wakefulness to
sleep,38,39 and as a consequence PaCO2, is closer to their
apneic threshold during sleep.39 Lorenzi-Filho et al.40 were
able to abolish Cheyne-Stokes in CHF patients by inhala-
tion of small concentrations of CO2 delivered by a mask.
Stabilization of breathing was achieved by a small (~2 mm
Hg) but significant increase in transcutaneous PCO2. In con-
trast, supplemental oxygen was not able to raise transcuta-
neous PCO2 and had no significant impact on the frequency
of Cheyne-Stokes.40 This study reveals the critical impor-
tance of small variations in PaCO2, which when it falls be-
low the apneic threshold triggers central apneas and
Cheyne-Stokes respiration. Arousals, through promotion of
hyperventilation, appear to facilitate rather than to provoke
periodic breathing directly.
The second question is: why do patients with CHF
hyperventilate? Several possible mechanisms, listed in Ta-
ble 1 and summarized in Figure 2, may participate. The most
important mechanisms will be discussed below.
Pulmonary congestion
There is a considerable body of evidence showing that
pulmonary congestion is associated with reduced PaCO2.
Tkacova et al.38 examined a population of patients with
CHF due to nonischemic dilated cardiomyopathy and
showed that, in spite of similar left ventricular ejection frac-
tions, the left ventricular (LV) end diastolic and systolic
volumes were twice as high in patients with Cheyne-Stokes
respiration as compared to those without it. In addition,
Cheyne-Stokes patients had a significantly lower PaCO2
while awake, and a lower mean transcutaneous CO2
(PtcCO2) during stage 2 sleep. Furthermore, the greater the
LV end-diastolic volume, the less the rise in PaCO2 from
wakefulness to stage 2 sleep. This relationship suggests that
marked LV dilatation in patients with nonischemic dilated
cardiomyopathy is associated with a nonchemical respira-
tory drive that prevents the normal rise in PaCO2 during
the transition from wakefulness to sleep. The most likely
explanation for this relationship is that high LV volumes
are associated with elevated LV filling pressures. These re-
sults are in line with the observation that pulmonary capil-
lary wedge pressure was significantly greater in patients with
CHF and Cheyne-Stokes respiration, as compared to CHF
patients with no sleep apnea or obstructive sleep apnea.12
We have also studied CHF patients undergoing diagnostic
cardiac catheterization, in which hemodynamic variables
and arterial blood gases were measured simultaneously.
PaCO2 correlated inversely with capillary wedge pressure
(r = –0.80, P = .003). In addition, in 3 patients in whom
multiple measurements were made, acute alterations in cap-
illary wedge pressure caused inversely proportional changes
in PaCO2.41 Therefore, hypocapnia in CHF patients is a res-
piratory manifestation of elevated LV filling pressures.
Pulmonary congestion stimulate ventilation and reduce
PaCO2 by mechanisms that are not completely understood.
Experiments in animals suggest that pulmonary venous con-
gestion and elevation of interstitial pressure cause increased
pulmonary vagal afferent nerve stimulation, which precipi-
tates central apnea followed by rapid shallow ventilation
with increased minute ventilation.42 These observations are
limited, however, and Cheyne-Stokes was not studied. Con-
gestive heart failure patients with Cheyne-Stokes respira-
tion have high central and peripheral chemo-
responsiviness.43,46,47 Elevated chemoreceptor responsive-
ness (gain) could destabilize the respiratory control system
by increasing the tendency to hyperventilate, promoting
both a background hypocapnia and also triggering a
ventilatory overshoot. Augmented gain of the chemo-
receptors, which could be primary or, more likely, second-
ary to pulmonary edema, destabilizes the respiratory con-
trol system by making it prone to ventilatory overshoot30,45
(Figure 2).
Prolonged circulatory time
Prolonged circulation time leading to delays in trans-
mitting changes of arterial blood gas tensions within the
lungs to the chemoreceptors could theoretically
Table 1 - Mechanisms responsible for respiratory stability
(STABLE) and instability (UNSTABLE) in congestive heart
failure patients
VENTILATION
Variable STABLE UNSTABLE
CHEMICAL FACTORS
PaCO2(apneic threshold) Above Close
Chemoreflex response Rapid Delayed
Adequate Increased
O2 and CO2 reservoir Large Low Functional
Residual Capacity
SLEEP FACTORS
Awake drive to breathe Present Absent during sleep
Continuity of sleep Present Arousals
337
CLINICS 2005;60(4):333-44 Cheyne-stokes respiration in patients with congestive heart failure
Lorenzi-Filho G et al.
destabilize the respiratory control system. It could do so
by changing a negative feedback into a positive feedback
system such that “the right response occurs at the wrong
moment”.48,49 In support of this theory, Guyton et al.48 in-
duced Cheyne-Stokes respiration in sedated dogs by in-
serting a length of tubing between the heart and brain to
prolong the transit time from the lungs to the
chemoreceptors. However, Cheyne-Stokes was achieved
only when the circulatory delay was a few minutes in du-
ration, far exceeding anything seen in patients with CHF.
There is now a body of evidence indicating that prolonged
circulatory delay is not the critical factor predisposing to
Cheyne-Stokes respiration. In humans, the circulatory de-
lay for a given chemical stimulus to reach the carotid
body from the lungs can be estimated by determining the
time from the end of an apnea until the maximum dip in
SaO2 detected by an oximeter on the ear (which is in close
proximity to the carotid body). This lung-to-ear circula-
tion time (LECT) is inversely proportional to the stroke
volume and cardiac output in both patients with normal
and with abnormal heart function.50 In this study, patients
with idiopathic central sleep apnea (ICSA), whose cardiac
function and LECT were normal, were compared to CHF
patients with Cheyne-Stokes. The results showed that de-
spite having higher stroke volumes and shorter LECT than
the CHF patients with Cheyne-Stokes, those with ICSA
had the same low and fluctuating PaCO2 and similar high
frequencies of central apnea during sleep. These data in-
dicate that central apneas in patients with ICSA and
Cheyne-Stokes are due to hypocapnia and fluctuations in
PaCO2 below and above the apnea threshold, but are not
related to the degree of circulatory delay. A number of in-
vestigators have also found no significant differences in
LECT or LVEF between CHF patients with and without
Cheyne-Stokes respiration-.21,22,3536 In the same study, Hall
et al. observed that the longer periodic breathing cycle
length in the CHF patients with Cheyne-Stokes respira-
tion was related to a longer LECT than in the patients with
idiopathic central sleep apnea. The relationship between
LECT and cycle length was found to be due to the corre-
lation of LECT and hyperpnea length, whereas LECT did
not correlate with apnea length. However, the characteris-
tic “sculpting” and prolongation of the hyperpnea in CHF
patients was related to their lower cardiac output. There-
fore, rather than initiating periodic breathing and central
apnea, circulatory delay appears to determine hyperpnea
length and, secondarily, cycle length once periodic breath-
ing with central apnea has been established. However, it
does not affect apnea length, which is influenced by the
degree of preceding hyperventilation and hypocapnia.51
Figure 2 - Schematic representation of the mechanisms involved in the genesis of Cheyne-Stokes respiration
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Hypoxia
One possible explanation for hyperventilation and low
PaCO2 is hypoxia. Normal subjects may present periodic
breathing during sleep at high altitude. In periodic breath-
ing at high altitude, hypoxemia causes hyperventilation
and lowers PaCO2 below the apnea threshold.52 Under
these conditions, administration of O2 removes the hy-
poxic drive, allowing PaCO2 to rise above the apneic
threshold and abolishing central apnea. The critical de-
pendence of periodic breathing at high altitude on fluc-
tuations in PaCO2 is further emphasized by the observa-
tion that CO2 inhalation, even in the presence of sustained
hypoxia, raises PaCO2 and abolishes central apnea. How-
ever, both awake PaO2 and mean nocturnal SaO2 in CHF
patients with Cheyne-Stokes respiration are within normal
limits and are practically identical to those in CHF pa-
tients without Cheyne-Stokes.35,36,37 Thus, the hypoxic dips
in Cheyne-Stokes respiration are the result, rather than the
cause, of central apnea. Nevertheless, the hypoxic dips
during apnea could further the tendency to hyperventilate
at the termination of central apnea by amplifying the
ventilatory response to CO2 once PaCO2 rises above the
ventilatory threshold.30 Ventilatory overshoot with propa-
gation of Cheyne-Stokes respiration would therefore be
facilitated by even mild degrees of apnea-related hypoxia.
Dips in SaO2 would also facilitate arousal from sleep, which
in turn contributes to hyperventilation.
A number of studies have investigated the effects of
supplemental oxygen in patients with CHF and Cheyne-
Stokes. It must be stressed that most studies were inter-
ested in abolishing the dips in SaO2 rather than under-
standing how such dips contribute to the genesis of
Cheyne-Stokes respiration.53-57 All studies were consistent
in showing small but significant reductions in the total
amount of Cheyne-Stokes respiration. For instance, Hanly
showed that low flow O2 administered to patients with
CHF reduced the duration of Cheyne-Stokes respiration-
CSA mainly during stage 1 sleep, with no significant
change during stage 2, slow wave, or rapid eye movement
(REM) sleep.55 The administration of O2 was also associ-
ated with a more consolidated sleep with a decrease in the
number of arousals. Modest reductions in the frequency
of central apneas and hypopneas in response to O2 admin-
istration have been confirmed by others.54-56 Differences
in the effects of O2 in Cheyne-Stokes respiration among
patients are most likely related to rising PaCO2 in response
to abolition of hypoxic drive. Taken together, these data
are consistent with the concept that hypoxia may play a
role in aggravating, but is not the major determinant of
Cheyne-Stokes in patients with CHF.
Contributing factors to respiratory instability
Two additional factors, namely low functional residual
capacity and upper airway instability may further contrib-
ute to respiratory instability and perpetuation of Cheyne-
Stokes respiration. Congestive heart failure patients have a
low functional residual capacity that is further reduced by
moving from the upright to the supine position. A large
functional residual capacity acts as a large reservoir of O2
and CO2 in the body and damps oscillations in PaO2 and
PaCO2 that would occur during apnea.45,58 Therefore, reduc-
tions in functional residual capacity decrease the lung O2
and CO2 reservoirs and allow greater reductions in PaO2 and
greater increases in PaCO2 during apnea.45,58 This could con-
tribute to instability of the respiratory control system. How-
ever, Naughton et al.35 have shown that lung volumes in
CHF patients with Cheyne-Stokes respiration do not differ
from those in patients without it. Thus the role of reduced
lung volume in the pathogenesis of Cheyne-Stokes remains
uncertain, and if present, will only help to make the respi-
ratory system unstable.
Upper airway instability may play a role in the
pathogenesis of Cheyne-Stokes. Alex et al.59 described up-
per airway occlusion at the onset and at the end of central
apnea in patients with CHF. Instability of upper airway re-
sistance could promote the development of respiratory in-
stability. If upper airway resistance increases as ventilation
decreases during the decrescendo phase of the hyperpneic
portion of Cheyne-Stokes respiration, there will be a ten-
dency to cause an undershoot of ventilation.60 The occa-
sional occluded breath at the onset of central apnea during
Cheyne-Stokes59 is compatible with this possibility. On the
other hand, decreasing resistance as ventilation increases
during the crescendo phase will facilitate overshoot, rap-
idly driving PaCO2 down and setting up conditions for post-
hyperventilation apnea. In addition, it is possible that up-
per airway collapse itself can reflexly precipitate central
apnea.62 This suggests an important interaction between
upper airway and central controller instability in the
pathogenesis of some cases of Cheyne-Stokes respiration.
Consistent with this hypothesis, Sahlin et al.,63 studying the
overnight polysomnography of 20 patients presenting
Cheyne-Stokes, observed that the frequency of apneas and
hypopneas in patients with this respiration was signifi-
cantly higher when patients were in the supine position. It
is noteworthy in this context that continuous positive air-
way pressure (CPAP), which dilates and stabilizes the up-
per airway,64,65 has been shown to alleviate Cheyne-
Stokes.66,67,68 These data must be interpreted with caution
because CPAP has many other effects that could damp pe-
riodic breathing by a indirect mechanism other than
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stabilization of the upper airway. Continuous positive air-
way pressure is an effective treatment for the failing heart,
not only because it inflates the lungs but also because it
augments cardiac performance by decreasing pre and after
load.69,70 On the other hand, the recent observation that
Cheyne-Stokes respiration is more frequent in the supine
position is compelling evidence that upper airway insta-
bility does play a role in the aggravation of the respiration,
at least in some patients.
CONSEQUENCES OF CHEYNE-STOKES
RESPIRATION
Cheyne-Stokes respiration is the consequence of a fail-
ing heart. Accordingly, Cheyne-Stokes is ameliorated by
therapies that improve myocardial function, such as cardiac
resynchronization in patients with CHF associated with
conduction disturbances,71 and goes away after heart trans-
plant.72 One important question raised is: once established,
does Cheyne-Stokes respiration constitute an additional
burden to the patient? It is now recognized that it gives
rise to clinical problems largely through its effects during
sleep, in agreement with the observations of Harrison et al.73
These effects are similar to those associated with sleep apnea
syndromes and lead to disrupted sleep and its consequences.
Hanly et al.74 showed that patients with CHF and Cheyne-
Stokes had a sleep latency that was significantly shorter
than CHF patients without this breathing disorder, suggest-
ing that they suffered from hypersomnolence. In addition,
they demonstrated that patients with CHF and Cheyne-
Stokes had more stage 1 and 2 nonREM sleep, less REM
sleep, and a higher frequency of arousals from sleep than
CHF patients without the breathing disorder.72 Interestingly
enough, CHF patients with Cheyne-Stokes respiration14 and
obstructive sleep apnea75 do not complain of significant
subjective sleepiness. The symptoms may overlap with the
fatigue that is characteristic in patients with severe CHF.
There is some evidence suggesting that Cheyne-Stokes
respiration is a marker of poor prognosis in patients with
CHF, but the data is conflicting. Findley et al. reported in an
uncontrolled retrospective study that patients with CHF who
also suffered from Cheyne-Stokes during sleep had a higher
mortality rate than patients without it. Hanly et al.22 prospec-
tively followed a group of 16 patients with stable CHF, 9 of
whom had Cheyne-Stokes respiration and 7 of whom did not.
Despite comparable LVEF, the combined rate of mortality and
heart transplantation was significantly higher in the Cheyne-
Stokes group. Similarly, Sin et al.23 observed an increased
mortality in CHF patients presenting Cheyne-Stokes respi-
ration. These data suggest that Cheyne-Stokes itself may ac-
celerate disease progression in patients with heart failure.
Conversely, Andreas et al.73 did not observe increased mor-
tality in patients presenting Cheyne-Stokes respiration dur-
ing the night, but only in patients presenting it while awake.
Rebuck et al. followed 78 patients, of whom 42% had
Cheyne-Stokes, over a median period of 52 months. The au-
thors were able to confirm an increased mortality in patients
presenting sleep disorder breathing (including obstructive
sleep apnea, present in 28%) at 500 days, but contrary to
their initial hypothesis, the effect was lost at long-term fol-
low-up (52 months).77 Therefore, the effects of Cheyne-Stokes
respiration during sleep in patients with CHF remain to be
established. It is possible that respiratory instability while
awake is more meaningful for mortality than while asleep.
Supporting this hypothesis, we have observed that periodic
breathing during exercise (a mild form of Cheyne-Stokes)
was a powerful predictor of mortality in CHF patients wait-
ing for heart transplant.3
Regardless of the exact impact of Cheyne-Stokes on
mortality, there is evidence that it may be detrimental to
the failing heart. Blood pressure (BP) and heart rate (HR)
oscillate in concert with Cheyne-Stokes cycles, very much
as they do during obstructive sleep apnea; that is, peaks
occur during the hypernea and troughs during apnea.56,78
These oscillations could be related to the same mechanisms
that have been implicated in obstructive sleep apnea, in-
cluding hypoxia and arousals from sleep, both of which can
stimulate sympathetic nerve activity. However, Franklin et
al. and Leung et al. 20 found that O2 administration at a suf-
ficient flow rate to abolish dips in SaO2 did not significantly
influence BP or HR oscillations during Cheyne-Stokes res-
piration. These data indicate that mechanisms other than
hypoxic dips are involved in precipitating these surges in
BP and HR during Cheyne-Stokes. The best explanation
for the oscillations in BP and HR during Cheyne-Stokes is
related to the intrinsic link between ventilation and the car-
diovascular system, which, for instance, also produces os-
cillations in BP and HR on a breath-to-breath basis. Nor-
mal subjects voluntarily reproducing a Cheyne-Stokes res-
piratory pattern of breathing (in the absence of hypoxia or
arousals from sleep) presented profound oscillations in BP
and HR in a pattern that was similar to what is seen in CHF
patients during Cheyne-Stokes respiration.18 Trinder et al.75
also found that BP oscillations during Cheyne-Stokes in
CHF were related to oscillations in ventilation and not to
the level of hypoxia. Moreover, when Cheyne-Stokes was
abolished by the inhalation of small concentrations of CO2,
oscillations in BP and HR were also abolished.20 Regard-
less of the exact mechanisms, once established, Cheyne-
Stokes promotes cyclic increases in BP and HR in concert
with the ventilatory cycle,20,56,78 which may contribute to a
poor prognosis for CHF patients with Cheyne-Stokes.
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Hypoxia and arousals from sleep present during Cheyne-
Stokes may also be associated with stimulation of the sym-
pathetic nervous system. Overnight urinary norepinephrine
concentrations and daytime plasma norepinephrine concen-
trations are markedly higher in CHF patients with Cheyne-
Stokes than in those without it, and they are directly re-
lated to the frequency of arousals from sleep and to the de-
gree of apnea-related hypoxia, but not to left ventricular
ejection fraction.79 These data suggest that Cheyne-Stokes
can trigger sympathetic activation in patients with CHF.
These higher nocturnal and daytime catecholamine concen-
trations might aggravate myocardial dysfunction. On the
other hand, Mansfield et al.80 studied 55 CHF patients and
showed that Cheyne-Stokes breathing was associated with
worse cardiac function (higher mean pulmonary artery pres-
sure) and higher total body plasma and cardiac norepine-
phrine. The differences in norepinephrine were due to heart
failure and not to apnea severity. Cheyne-Stokes respira-
tion could therefore be a marker of poor prognosis rather
than a causative factor. This hypothesis fits with the obser-
vation that CHF patients with this breathing disorder have
larger left ventricles than those without it.81 Javaheri et al.
also observed that Cheyne-Stokes is associated with a lower
PaCO2 and a higher rate of ventricular tachycardia.37 These
associations do not clarify whether there is any relation-
ship of causality between Cheyne-Stokes and poor prog-
nosis, and further studies are needed.
The discussion of the treatment of Cheyne-Stokes respi-
ration in patients with CHF is beyond the scope of this re-
view. Readers wishing an in depth discussion of this subject
are referred to a recent review.82 Briefly, since Cheyne-Stokes
respiration probably arises from CHF, the first approach to
therapy is to optimize the medical therapy of CHF.83 Failing
that, there are a number of other therapeutic options. The most
extensively tested intervention is CPAP. When used overnight
for 1 to 3 months, CPAP has been shown to alleviate Cheyne-
Stokes; to increase LVEF; reduce mitral regurgitation, atrial
natriuretic peptide and both urinary and plasma norepine-
phrine levels. It also improved quality of life and sur-
vival.23,67,68,79,84,85 Oxygen administration has been shown to
cause a modest reduction in the severity of Cheyne-Stokes
respiration, to reduce overnight urinary norepinephrine lev-
els, and cause an increase in peak O2 consumption during
graded exercise over periods of 1 to 4 weeks.53-57 Finally, theo-
phylline has been shown to reduce the severity of Cheyne-
Stokes over 5 days, but has not been shown to improve car-
diac function, neurohumoral activity, or quality of life.86
Pepperell et al. have recently shown in a prospective
randomized trial that 1 month of nocturnal-assist
servoventilation was able to reduce daytime sleepiness in
conjunction with improvements in plasma brain natriuretic
peptide and urinary metadrenaline excretion in patients with
CHF and Cheyne-Stokes.87 Larger, longer-term randomized
trials will be required to determine which, if any, of these
interventions are effective for the management of CHF pa-
tients with Cheyne-Stokes respiration.88
RESUMO
Lorenzi-Filho G, Genta PR, Figueiredo AC, Inoue D. A
respiração de Cheyne-Stokes em pacientes com insuficiência
cardíaca congestiva: causas e conseqüências. Clinics.
2005;60(4): 333-44.
A respiração de Cheyne-Stokes é uma forma de respiração
periódica na qual apnéias e hipopnéias se alternam com
períodos de hiperpnéias que apresentam um padrão cre-
scendo e decrescendo de volume corrente. Esta revisão
enfoca as causa e conseqüências da respiração de Cheyne-
Stokes em pacientes com insuficiência cardíaca congestiva
na qual a prevalência é extremamente alta e varia entre 30
a 50%. Vários fatores foram implicados na gênese da
respiração de Cheyne-Stokes, incluindo baixo debito
cardíaco e hipoxia recorrente. Hiperventilacão e baixos
níveis de CO2 arterial (PaCO2), que quando abaixo do
limiar de apnéia desencadeiam apnéia central são os
mecanismos fisiopatológicos chave na gênese da respiração
de Cheyne-Stokes. Hiperventilação está associada com
congestão pulmonar, e a respiração de Cheyne-Stokes tem
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